| Filed On | Filing |
|---|---|
| 31 Mar 2025 | 15-12G |
| 25 Mar 2025 | EFFECT |
| 21 Mar 2025 | POS AM |
| 21 Mar 2025 | S-8 POS |
| 20 Mar 2025 | 25 |
| 07 Mar 2025 | SCHEDULE 13G/A |
| 24 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on February 10, 2025, Omega Therapeutics, Inc., a Delaware corporation (the “Company” or “Debtor”), filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Co... |
| 14 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +1 more
The information set forth below in Item 1.03 of this Current Report on Form 8-K (this “Form 8-K”) regarding the DIP Facility is incorporated herein by reference. All capitalized terms not otherwise defined in this Item 1.01 shall have th... |
| 05 Feb 2025 | 144 |
| 05 Feb 2025 | SCHEDULE 13D/A |
| 04 Feb 2025 |
Form 3: Varsalone Jeffrey T, Director
No securities owned |
| 03 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +4 more
On February 3, 2025, Omega Therapeutics, Inc. (the “Company”) entered into a Restructuring Support Agreement (together with all exhibits and schedules thereto, the “RSA”) with Pioneering Medicines 08-B, Inc. (the “Supporting Party”), an ... |
| 28 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 17 Jan 2025 |
8-K: Triggering Events That Accelerate a Financial Obligation
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. |
| 10 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 31 Dec 2024 | SCHEDULE 13D/A |
| 31 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On December 30, 2024, Michelle C. Werner notified Omega Therapeutics, Inc. (the “Company”) of her resignation as a member of the Board of Directors of the Company (the “Board”) and the Nominating and Corporate Governance Committee of the... |
| 06 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 3, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”) elected Ravi Mehrotra, Ph.D. as a Class II director of the Company, effective immediately. On the Effective Date... |
| 05 Dec 2024 |
Form 4: Mehrotra Ravi, Director
Granted 50,000 Stock Option (Right to Buy) |
| 05 Dec 2024 |
Form 3: Mehrotra Ravi, Director
No securities owned |
Loading...